NEW YORK (GenomeWeb News) – In a patent infringement suit between Illumina and Complete Genomics, the US District Court for the Northern District of California this week denied a motion by Illumina to reconsider a judgment the court rendered in favor of Complete Genomics last October.
The October ruling found certain claims of an Illumina patent to be invalid due to prior art.
The dispute between the firms began in 2010, when Illumina sued Complete Genomics, alleging infringement of three of its sequencing-related patents: US Patent No. 6,306,597; 7,232,656; and 7,598,035.
Last year, Judge Elizabeth Laporte of the US District Court for the Northern District of California issued a claims construction order only on the '597 patent. Then, in October, Laporte granted Complete Genomics a partial summary judgment, ruling that Claim 1 and dependent Claims 9, 10, 14, 15, 16, 17, 18, and 19 of the '597 patent were invalid.
After that ruling, Illumina petitioned the court to reconsider its ruling, contending that the court decision was "manifestly unjust."
The court considered Illumina's motion and this week issued its ruling, denying the appeal. In addition, it amended its original order for partial summary judgment "to correct two minor errors that do not affect the merits."